Ocular Therapeutix, Inc. announced 12-month data from its Phase 1 clinical trial evaluating OTX-TKI for the treatment of wet age-related macular degeneration (wet AMD), showing positive results and plans to initiate a pivotal trial in the third quarter of 2023.